AC Immune(US:ACIU)2023-04-27 16:00Financial Performance - The company reported a net loss of CHF 17,513 thousand for the three months ended March 31, 2023, compared to a net loss of CHF 18,848 thousand for the same period in 2022, indicating an improvement of approximately 7.1%[7] - The total comprehensive loss for the period was CHF 17,521 thousand, compared to CHF 18,838 thousand in the prior year, showing an improvement of approximately 7.0%[7] - For the three months ended March 31, 2023, the net loss attributable to equity holders was CHF 17,513 thousand, compared to a net loss of CHF 18,848 thousand for the same period in 2022, representing a decrease of approximately 7.1%[32] - The basic and diluted loss per share for the period was CHF 0.21, compared to CHF 0.23 for the same period in 2022, indicating an improvement of about 8.7%[32] Assets and Liabilities - Total assets decreased from CHF 185,938 thousand as of December 31, 2022, to CHF 169,150 thousand as of March 31, 2023, representing a decline of approximately 9.6%[2] - Shareholders' equity decreased from CHF 168,991 thousand to CHF 152,935 thousand, a reduction of about 9.5%[2] - Current assets decreased from CHF 128,094 thousand to CHF 111,688 thousand, a decline of about 12.8%[2] - Total liabilities slightly decreased from CHF 16,947 thousand to CHF 16,215 thousand, a reduction of approximately 4.3%[2] Cash Flow and Liquidity - Cash and cash equivalents increased significantly from CHF 31,586 thousand to CHF 57,434 thousand, a rise of approximately 81.7%[2] - Cash used in operating activities for the three months ended March 31, 2023, was CHF 16,769 thousand, a reduction of 27.3% from CHF 23,008 thousand in the same period of 2022[11] - The company reported net cash flows provided by investing activities of CHF 42,800 thousand for the three months ended March 31, 2023, compared to cash used of CHF 540 thousand in the same period of 2022[11] - The company believes it can meet its obligations for at least 12 months from the filing date, supported by a cash position of CHF 57.4 million and short-term financial assets of CHF 48.0 million[26] Expenses and Investments - Operating expenses for the period were CHF 17,571 thousand, down from CHF 18,830 thousand in the previous year, reflecting a decrease of about 6.7%[5] - The company invested CHF 0.2 million in laboratory and IT equipment during the first quarter of 2023, reflecting a 1.7% increase from the beginning of the year[5] - The total cash outflow for leases was CHF 458 thousand for the three months ended March 31, 2023, compared to CHF 333 thousand for the same period in 2022, an increase of 37.5%[38] Other Financial Metrics - The company recognized CHF 0.4 million in grant income for the three months ended March 31, 2023, consistent with the same amount recognized in the prior year[31] - The company has recorded CHF 0.3 million in deferred income as of March 31, 2023[31] - The company has not generated any contract revenues for the three months ended March 31, 2023[28] - The company recorded a currency translation difference loss of CHF 8 thousand for the period, compared to a gain of CHF 10 thousand in the previous year[7] - The company recorded net financial gains of CHF 0.1 million for the three months ended March 31, 2023, compared to less than CHF 0.1 million in net financial losses for the same period in 2022[48] Share Information - The weighted-average number of shares outstanding used to compute EPS was 83,625,826 for the three months ended March 31, 2023, compared to 83,486,354 for the same period in 2022[32]